Zacks Investment Research upgraded shares of Celyad Oncology (NASDAQ:CYAD – Get Rating) from a hold rating to a buy rating in a research note issued to investors on Wednesday morning, Zacks.com reports. The brokerage currently has $2.25 target price on the stock.
According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
Separately, HC Wainwright cut Celyad Oncology from a buy rating to a neutral rating and set a $2.78 price objective for the company. in a research report on Monday, February 28th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Hold and an average price target of $5.34.
An institutional investor recently raised its position in Celyad Oncology stock. Wells Fargo & Company MN lifted its position in Celyad Oncology SA (NASDAQ:CYAD – Get Rating) by 139.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,635 shares of the company’s stock after purchasing an additional 10,850 shares during the quarter. Wells Fargo & Company MN owned 0.12% of Celyad Oncology worth $69,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 41.14% of the company’s stock.
Celyad Oncology Company Profile (Get Rating)
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
- Get a free copy of the StockNews.com research report on Celyad Oncology (CYAD)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.